ArticleCellular and molecular gastroenterology and hepatology2026
Interleukin13 Ameliorates Hepatocellular Steatosis via IL13Rα1/JNK/FOSL2 Signaling Pathway.
Article in Cellular and molecular gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsSevere obesity is a major global health challenge and a key driver of hepatic steatosis through systemic insulin resistance and enhanced de novo lipogenesis. Excessive hepatic triglyceride accumulation represents a central metabolic consequence of this condition. This study aimed to identify immune-derived regulators of liver lipid metabolism and to define the mechanistic role of interleukin13 (IL13) in obesity-associated liver disease progression.
methodsIL13 levels and related signaling pathways were analyzed in plasma samples from patients with ≥class II obesity and liver biopsies from patients with hepatic steatosis and steatohepatitis. The effects of IL13 depletion on lipid metabolism were examined in mice, whereas its mechanistic role in fat metabolism was studied in primary hepatocytes.
resultsIn a cohort of severely obese patients, plasma IL13 levels rose after weight loss and were positively associated with fibroblast growth factor 19 (FGF19), fibroblast growth factor 21 (FGF21), and insulin-like growth factor-1 (IGF1). IL13-deficient mice showed worsened liver triglyceride accumulation, lower polyunsaturated fatty acids, and altered expression of peroxisome proliferator-activated receptor-dependent lipid genes. Primary murine hepatocytes revealed that IL13 decreases triglyceride content through interleukin13Rα1 (IL‑13Rα1) and a c-Jun N-terminal kinase (JNK)-dependent c-JUN-FOS-like antigen 2 (FOSL2) axis, which enhances β-oxidation and ketogenesis. FOSL2 was required for maximal peroxisome proliferator-activated receptor (PPAR) activity and was upregulated in livers of patients with hepatic steatosis and steatohepatitis.
conclusionsThese data demonstrate that IL13 is a critical immunometabolic regulator of hepatic lipid homeostasis. Targeting the IL‑13-FOSL2-PPAR signaling pathway may offer a novel therapeutic approach to reduce hepatic steatosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.